Please assess the completion status of the following clinical trial:

Trial Title: BI 671800 in Asthmatic Patients on Inhaled Corticosteroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Signed informed consent consistent with ICH-GCP~2. Three month history of reversible (12% and 200 mL in forced expiratory volume in one second - FEV1) asthma (according to GINA) with following spirometry at randomisation: FEV1 60%- 85%.~3. Stable inhaled corticosteroids (iCS) dose 3 months prior to screening.~4. Diagnosis of asthma prior to 40 years.~5. Asthma Control Questionnaire (ACQ) at least 1.5 at randomisation.~6. Male or female 18 to 65 years.~7. Non-smokers or ex-smokers (less than 10 pack years history) with negative cotinine screen.~8. Able to perform pulmonary function testing.~Exclusion criteria:~1. Significant diseases other than asthma or allergic rhinitis.~2. Hepatic transaminases or total bilirubin greater than 1.5 ULN.~3. Hospitalisation for asthma exacerbation or asthma related intubation within 3 months.~4. Uncontrolled asthma on iCS + other controller.~5. Respiratory tract infection or exacerbation within 4 weeks.~6. FEV1 less than 40%, more than 12 puffs rescue salbutamol on more than two consecutive days, or asthma exacerbation during run-in period.~7. Participation in another interventional study.~8. Pregnant or nursing women.~9. Women of child bearing potential not using appropriate methods of birth control as defined by the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BI 671800 (Type: EXPERIMENTAL): Patients receive BI 671800 capsules twice daily
- Montelukast (Type: ACTIVE_COMPARATOR): Patients receive Montelukast encapsulated tablets once daily
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive placebo capsules and/or encapsulated placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).